Evolus (EOLS) Revenue (2019 - 2026)
Evolus' (EOLS) quarterly Revenue came in at $84.1 million in Q2 2026, up 21.18% on a YoY basis from $69.4 million in Q2 2025, and up 14.97% quarter-over-quarter from $73.1 million in Q1 2026.
Analysis
Evolus (EOLS) Revenue (2019 - 2026) Analysis & Trends
Evolus (EOLS) has reported Revenue for 8 consecutive years, with $84.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue rose 21.18% year-over-year to $84.1 million; the trailing twelve-month figure through Jun 2026 stood at $316.5 million (up 13.87% YoY), and the FY2025 full-year result was $297.2 million, up 11.61% from the prior year.
- Revenue grew to $84.1 million in Q2 2026 per EOLS's latest filing, from $73.1 million in the prior quarter.
- Across five years, Revenue topped out at $90.3 million in Q4 2025 and bottomed at $33.9 million in Q3 2022.
- Historically, Revenue has averaged $59.5 million across 5 years, with a median of $61.0 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Revenue surged 177.0% in 2022, then gained 3.7% in 2025.
- Over 5 years, Revenue stood at $43.6 million in 2022, then soared by 39.76% to $61.0 million in 2023, then increased by 29.42% to $78.9 million in 2024, then climbed by 14.38% to $90.3 million in 2025, then dropped by 6.88% to $84.1 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $84.1 million, $73.1 million, and $90.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | 15.03 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 13.48 Bn |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | - |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 1.67 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 783.30 Mn |
| 10 | Evolus | 567.65 Mn | 522.48 Mn | 57.18 Mn | 84.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 84.08 Mn |
| Mar 31, 2026 | 73.14 Mn |
| Dec 31, 2025 | 90.30 Mn |
| Sep 30, 2025 | 68.97 Mn |
| Jun 30, 2025 | 69.39 Mn |
| Mar 31, 2025 | 68.52 Mn |
| Dec 31, 2024 | 78.95 Mn |
| Sep 30, 2024 | 61.09 Mn |
| Jun 30, 2024 | 66.91 Mn |
| Mar 31, 2024 | 59.33 Mn |
| Dec 31, 2023 | 61.00 Mn |
| Sep 30, 2023 | 50.02 Mn |
| Jun 30, 2023 | 49.35 Mn |
| Mar 31, 2023 | 41.72 Mn |
| Dec 31, 2022 | 43.65 Mn |
| Sep 30, 2022 | 33.90 Mn |
| Jun 30, 2022 | 37.16 Mn |
| Mar 31, 2022 | 33.91 Mn |
| Dec 31, 2021 | 34.66 Mn |
| Sep 30, 2021 | 26.68 Mn |